Literature DB >> 23447628

Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.

Robert G Mealer1, Srinivasa Subramaniam, Solomon H Snyder.   

Abstract

Although the mutated protein causing Huntington's disease (HD) is expressed throughout the body, the major pathology of HD is localized to the striatum of the brain. We previously reported that the striatal-enriched protein Rhes binds the mutated huntingtin protein and enhances its cytotoxicity. We now demonstrate that Rhes-deleted mice are dramatically protected from neurotoxicity and motor dysfunction in a striatal-specific model of HD elicited by 3-nitropropionic acid. This finding suggests that Rhes may, in part, determine the striatal selectivity of HD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23447628      PMCID: PMC3667505          DOI: 10.1523/JNEUROSCI.3730-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  26 in total

1.  The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons.

Authors:  Francesco Errico; Emanuela Santini; Sara Migliarini; Anders Borgkvist; Diego Centonze; Valentina Nasti; Manolo Carta; Valentina De Chiara; Chiara Prosperetti; Daniela Spano; Denis Herve; Massimo Pasqualetti; Roberto Di Lauro; Gilberto Fisone; Alessandro Usiello
Journal:  Mol Cell Neurosci       Date:  2007-10-23       Impact factor: 4.314

2.  Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity.

Authors:  Srinivasa Subramaniam; Katherine M Sixt; Roxanne Barrow; Solomon H Snyder
Journal:  Science       Date:  2009-06-05       Impact factor: 47.728

3.  A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model.

Authors:  Andrey S Tsvetkov; Jason Miller; Montserrat Arrasate; Jinny S Wong; Michael A Pleiss; Steven Finkbeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-10       Impact factor: 11.205

Review 4.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

5.  Does Huntingtin play a role in selective macroautophagy?

Authors:  Joan S Steffan
Journal:  Cell Cycle       Date:  2010-09-01       Impact factor: 4.534

6.  Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat.

Authors:  E Brouillet; M C Guyot; V Mittoux; S Altairac; F Condé; S Palfi; P Hantraye
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

7.  A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists.

Authors:  David Blum; Marie-Christine Galas; Annita Pintor; Emmanuel Brouillet; Catherine Ledent; Christa E Muller; Kadiombo Bantubungi; Mariangela Galluzzo; David Gall; Laetitia Cuvelier; Anne-Sophie Rolland; Patrizia Popoli; Serge N Schiffmann
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

8.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.

Authors:  Brinda Ravikumar; Coralie Vacher; Zdenek Berger; Janet E Davies; Shouqing Luo; Lourdes G Oroz; Francesco Scaravilli; Douglas F Easton; Rainer Duden; Cahir J O'Kane; David C Rubinsztein
Journal:  Nat Genet       Date:  2004-05-16       Impact factor: 38.330

Review 9.  Control of autophagy as a therapy for neurodegenerative disease.

Authors:  Harry Harris; David C Rubinsztein
Journal:  Nat Rev Neurol       Date:  2011-12-20       Impact factor: 42.937

Review 10.  Autophagy and polyglutamine diseases.

Authors:  Maria Jimenez-Sanchez; Frances Thomson; Eszter Zavodszky; David C Rubinsztein
Journal:  Prog Neurobiol       Date:  2011-09-10       Impact factor: 11.685

View more
  22 in total

1.  Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease.

Authors:  Juan I Sbodio; Bindu D Paul; Carolyn E Machamer; Solomon H Snyder
Journal:  Cell Rep       Date:  2013-09-05       Impact factor: 9.423

2.  Rhes suppression enhances disease phenotypes in Huntington's disease mice.

Authors:  John H Lee; Matthew J Sowada; Ryan L Boudreau; Andrea M Aerts; Daniel R Thedens; Peg Nopoulos; Beverly L Davidson
Journal:  J Huntingtons Dis       Date:  2014

3.  RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network ("Rhesactome") in the striatum.

Authors:  Neelam Shahani; Supriya Swarnkar; Vincenzo Giovinazzo; Jenny Morgenweck; Laura M Bohn; Catherina Scharager-Tapia; Bruce Pascal; Pablo Martinez-Acedo; Kshitij Khare; Srinivasa Subramaniam
Journal:  Sci Signal       Date:  2016-11-15       Impact factor: 8.192

4.  Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.

Authors:  John H Lee; Luis Tecedor; Yong Hong Chen; Alex Mas Monteys; Matthew J Sowada; Leslie M Thompson; Beverly L Davidson
Journal:  Neuron       Date:  2014-12-31       Impact factor: 17.173

5.  Histone H2AX promotes neuronal health by controlling mitochondrial homeostasis.

Authors:  Urbain Weyemi; Bindu D Paul; Deeya Bhattacharya; Adarsha P Malla; Myriem Boufraqech; Maged M Harraz; William M Bonner; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-25       Impact factor: 11.205

6.  Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy.

Authors:  Robert G Mealer; Alexandra J Murray; Neelam Shahani; Srinivasa Subramaniam; Solomon H Snyder
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

7.  Loss of Hap1 selectively promotes striatal degeneration in Huntington disease mice.

Authors:  Qiong Liu; Siying Cheng; Huiming Yang; Louyin Zhu; Yongcheng Pan; Liang Jing; Beisha Tang; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

Review 8.  Activators of G protein signaling exhibit broad functionality and define a distinct core signaling triad.

Authors:  Joe B Blumer; Stephen M Lanier
Journal:  Mol Pharmacol       Date:  2013-12-03       Impact factor: 4.436

Review 9.  Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Authors:  Jordi Creus-Muncunill; Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 10.  Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction.

Authors:  Jeremy M Henley; Tim J Craig; Kevin A Wilkinson
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.